When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Viewpoint - Afya Limited has received authorization from the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education to increase medical seats at ITPAC by 63, enhancing its capacity in medical education in Brazil [1]. Company Summary - Afya Limited is recognized as the leading medical education group and provider of medical practice solutions in Brazil [1]. - The increase of 63 medical seats at ITPAC, located in Abaetetuba, signifies a strategic expansion in the company's educational offerings [1].

Core Viewpoint - Top Wall Street analysts have revised their outlook on several key stocks, indicating potential investment opportunities in the market [1] Company Analysis - Analysts are considering SNDK stock as a potential buy, reflecting a positive sentiment towards the company's future performance [1]

Board of Directors - The company has a diverse board of directors consisting of co-chairmen Nicolau Carvalho Esteves and Kay Krafft, along with several directors including Benedikt Dalkmann, Christina Krebs, Renato Tavares Esteves, João Paulo Seibel de Faria, and independent directors Vanessa Claro Lopes, Miguel Filisbino Pereira de Paula, and Marcelo Ken Suhara [1]

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article highlights that users may face access issues if they have an ad-blocker enabled, suggesting the need to disable it for a better experience [1]

Core Viewpoint - Afya reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, marking an earnings surprise of +18.75% [1][2] Financial Performance - The company posted revenues of $170.44 million for the quarter ended September 2025, which was slightly below the Zacks Consensus Estimate by 0.16%, compared to $151.71 million in the same quarter last year [2] - Over the last four quarters, Afya has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Afya shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current Zacks Rank for Afya is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $172.53 million, and for the current fiscal year, it is $1.71 on revenues of $687.12 million [7] - The trend of estimate revisions for Afya was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Schools industry, to which Afya belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Afya Limited reported strong financial results for Q3 and the first nine months of 2025, reaffirming its full-year guidance and demonstrating significant growth in revenue and adjusted EBITDA margins [1][4][10]. Financial Performance - Q3 2025 revenue increased by 10.4% year-over-year to R$928.5 million, while revenue excluding acquisitions rose by 10.1% to R$926.2 million [4][25]. - For the nine-month period, revenue reached R$2,784.3 million, reflecting a 13.4% increase year-over-year, with revenue excluding acquisitions growing by 9.8% to R$2,696.7 million [4][25]. - Adjusted EBITDA for Q3 2025 was R$398.9 million, up 14.6% year-over-year, with an adjusted EBITDA margin of 43.0%, an increase of 160 basis points [4][28]. - For the nine-month period, adjusted EBITDA increased by 18.5% to R$1,291.7 million, with a margin of 46.4%, up 200 basis points [4][28]. Net Income and Earnings - Q3 2025 net income rose by 28.4% to R$159.4 million, while adjusted net income increased by 16.5% to R$192.7 million [4][32]. - For the nine-month period, net income reached R$593.0 million, a 19.9% increase, and adjusted net income was R$696.0 million, up 11.1% [4][32]. Cash Flow and Debt Management - As of September 30, 2025, cash and cash equivalents totaled R$996.8 million, a 9.4% increase from the previous year, with net debt reduced to R$1,342.2 million [4][36]. - The operating cash conversion ratio was 101.5%, with cash flow from operating activities increasing by 10.6% year-over-year to R$1,291.5 million [4][37]. Strategic Initiatives - The company has made significant advancements in its integrated ecosystem, focusing on enhancing educational services and medical practice solutions [5][10]. - Afya has launched AI-enabled enhancements to its platforms, supporting clinical productivity and decision-making [8]. - The company issued R$1.5 billion in commercial notes to strengthen its capital structure and repurchased shares from SoftBank, demonstrating a disciplined approach to capital management [9][41]. Segment Performance - The Undergraduate segment saw a 14.6% increase in revenue, driven by higher ticket prices and increased student enrollment [4][15]. - Continuing Education experienced growth in B2B revenue, while Medical Practice Solutions reported an increase in active payers, reflecting the value of its offerings [7][19].

Financial Data and Key Metrics Changes - Revenue for the nine-month period grew over 13% year over year, reaching BRL 2,784 million, with adjusted EBITDA growth of almost 19% year over year, reaching BRL 1,292 million [5][19] - Adjusted EBITDA margin for the same period reached 46.4%, an increase of 200 basis points over last year [5][19] - Net income reached BRL 593 million, a growth of 20% year over year, with basic EPS reaching BRL 6.40, also a 20% increase [6][21] - Cash flow from operating activities rose by 11%, ending the nine-month period at BRL 1,292 million, with a cash conversion of 101.5% [5][20] Business Line Data and Key Metrics Changes - The undergraduate segment saw a 6% growth in the number of medical students, reaching over 25,000, while approved medical seats increased by almost 2% [6][13] - Continuing Education segment revenue grew by 11% year over year, reaching BRL 208 million [7][15] - Medical Practice Solutions revenue increased over 9% year over year, reaching BRL 128 million [7][16] - The ecosystem reached 304,000 active users, indicating strong engagement among physicians and medical students [7][17] Market Data and Key Metrics Changes - The number of paying users in Medical Practice Solutions reached 195,000, a 2% decrease year over year, while monthly active users accounted for 228,000, down from 249,000 [16] - Continuing education saw a 36% decrease in residency journey students, while graduate journey students grew by 26% [15][66] Company Strategy and Development Direction - The company aims to maintain leadership in medical education and expand its ecosystem, focusing on sustainable growth and social impact through initiatives like Instituto AFIA [10][11] - The company is exploring M&A opportunities and evaluating capital allocation strategies, including potential increases in dividends and share buybacks [31][38] Management's Comments on Operating Environment and Future Outlook - Management expects effective tax rates to converge to 15% from 2026 onwards due to new tax regulations [30] - The company remains optimistic about future growth opportunities and is confident in its ability to create value for shareholders [25][40] Other Important Information - The company has been recognized for its ESG initiatives, receiving the Valor 1,000 award for its performance in the education sector [11] - The company has strengthened its financial position through liability management, including the issuance of commercial notes [22][23] Q&A Session Summary Question: Effective tax rate and capital allocation strategy - The effective tax rate for the nine-month period was 9.7%, up from 5.1% last year, primarily due to provisions for new tax regulations [29] - The company is evaluating various capital allocation strategies, including M&A, buybacks, and dividends [32] Question: Capital allocation strategies and 2026 intake cycle - The company is analyzing M&A opportunities and plans to maintain around 200 approved medical seats per year [38] - Tuition for 2026 is expected to increase by around 5% to 5.2% over 2025 [40] Question: Ticket readjustment and demand for medical careers - The average ticket is expected to grow around 5%, with demand for medical careers remaining stable compared to last year [44][45] Question: Gross margins in Medical Practice Solutions and subscriber trends - Gross margins in Medical Practice Solutions increased due to cost management initiatives [50] - The company is reviewing its pricing strategy for clinical decision software to regain subscriber growth [52] Question: Recently acquired units and EBITDA margin expansion - The ramp-up for recently acquired units is expected to take time, with margins improving as student numbers increase [61] - The company has achieved significant margin expansion and continues to seek efficiencies across its segments [66] Question: Continuing education segment trends - The drop in residency journey students is a one-time effect due to a change in product offerings [67]

Financial Performance - Revenue reached R$2,784.3 million, a 13.4% year-over-year increase for the nine-month period[7] - Adjusted EBITDA was R$1,291.7 million, up 18.5% year-over-year, with an adjusted EBITDA margin of 46.4%, a 200 bps increase[7] - Net income increased by 19.9% year-over-year to R$593.0 million, with earnings per share at R$6.40, a 19.7% increase[7] - Cash flow from operating activities increased by 10.6% year-over-year to R$1,291.5 million, with an operating cash conversion ratio of 101.5%[7] Operational Metrics - Medical school students totaled 25,706 at the end of the period[7] - Approved medical school seats reached 3,653[7] - Continuing education revenue increased by 10.6% year-over-year to R$207.6 million[7] - Medical practice solutions revenue increased by 9.3% year-over-year to R$128.2 million[7] Debt and Liabilities - New debenture issuance of R$1.5 billion to fund repurchase of preferred shares and prepay first debenture issuance[36, 37] - Total gross debt was R$2,339 million[38] ESG Initiatives - Delivered 700,000 free healthcare consultations, including over 500,000 medical consultations[10]

Financial Performance - Revenue for the three-month period ended September 30, 2025, increased to R$928,505, a 10.4% rise from R$841,185 in the same period of 2024[4] - Gross profit for the nine-month period ended September 30, 2025, reached R$1,819,003, up 17.6% from R$1,546,885 in 2024[4] - Net income for the nine-month period ended September 30, 2025, was R$592,999, representing a 20.2% increase compared to R$494,641 in 2024[4] - Revenue for the nine-month period ended September 30, 2025, was R$2,795,024, a 13.6% increase from R$2,460,916 in the same period of 2024[39] - Net income for the nine-month period ended September 30, 2025, was R$592,999, reflecting a 19.9% increase compared to R$494,641 in the same period of 2024[39] - For the nine-month period ended September 30, 2025, net income attributable to equity holders of the parent was R$579,499, compared to R$481,583 for the same period in 2024, representing a year-over-year increase of 20.3%[113] - Basic earnings per share for the nine-month period ended September 30, 2025, was R$6.40, compared to R$5.35 in 2024, marking an increase of 19.6%[4] Assets and Liabilities - Total assets as of September 30, 2025, amounted to R$9,187,159, an increase of 4.1% from R$8,829,539 at the end of 2024[2] - Total current liabilities increased to R$1,800,271, a significant rise of 57.9% from R$1,140,195 at the end of 2024[2] - Total equity attributable to equity holders of the parent increased to R$4,746,073 as of September 30, 2025, from R$4,269,955 at the end of 2024, reflecting an increase of 11.2%[2] - Current liabilities as of September 30, 2025, were R$1,811,030, compared to R$1,148,783 as of December 31, 2024, indicating a significant increase of 57.7%[34] - Total financial liabilities as of September 30, 2025, amounted to R$5,611,224, with loans and financing contributing R$2,304,184 and lease liabilities at R$2,218,793[90] Cash Flow and Financial Position - Cash and cash equivalents at the end of the period were R$996,826, up from R$911,015 at the end of 2024, reflecting an increase of 9.4%[2] - The company reported a net cash flow from operating activities of R$1,277,763 for the nine-month period ended September 30, 2025, compared to R$1,148,175 in 2024, an increase of 11.3%[8] - The company incurred finance expenses of R$433,049 for the nine-month period ended September 30, 2025, compared to R$322,420 in 2024, indicating a rise of 34.4%[4] - The net finance result for the nine-month period ended September 30, 2025, was a loss of R$289,386, compared to a loss of R$242,761 in 2024[118] Acquisitions and Expansion - Afya Limited acquired Unidom Participações S.A. for a total consideration of R$620,762, which includes R$340,773 paid in cash and R$279,989 payable in up to ten annual installments[12][14] - The acquisition of Unidom added 300 operational medical school seats, with 125 seats authorized and 175 seats pending final court confirmation[13] - Afya Brazil acquired Faculdade Masterclass Ltda. for R$100,000, contributing an additional 60 medical school seats, with R$60,000 paid in cash and R$40,000 payable in three annual installments[16][17] - The company plans to continue expanding its educational offerings, including increasing medical school seats, which will require additional investments[59] Educational Operations - As of September 30, 2025, Afya had a total of 3,603 operating medical school seats across its institutions[20] - The primary revenue source for Afya is from its operational companies in Brazil, with the Brazilian Real as the functional currency[22] - The company operates through three reportable segments: Undergraduate, Continuing Education, and Medical Practice Solutions[29][30] Tax and Compliance - The effective income tax rate for the nine-month period ended September 30, 2025, was 9.7%, compared to 5.1% in 2024[127] - The company recognized an additional income tax expense of R$84,419 for the nine-month period due to the OECD's Pillar Two global minimum tax[124] - The company had no breaches of financial and non-financial covenants for any loans and financing during the current period, ensuring compliance with all obligations[93] Shareholder Information - The company approved dividends of R$60,471 for the nine-month period ended September 30, 2025, compared to R$58,236 in the same period of 2024, marking an increase of 3.9%[106] - The weighted average number of outstanding shares for the nine-month period ended September 30, 2025, was 90,524,215, an increase from 90,083,878 in the same period of 2024[113] - The outstanding treasury shares were 3,025,116, down from 3,493,238 as of September 30, 2024, reflecting a reduction of 13.4%[109] Other Financial Metrics - Tuition fees for the nine-month period ended September 30, 2025, reached R$3,510,791, up 16.7% from R$3,008,529 in 2024[114] - Total costs and expenses for the nine-month period ended September 30, 2025, were R$1,843,877, an increase of 8.9% from R$1,693,382 in 2024[117] - The company’s payroll expenses for the nine-month period ended September 30, 2025, were R$1,025,502, an increase from R$927,717 in 2024[117]